Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Lawyers Pursue Skin Cancer Cases After Medication Use

By: NewsUSA

(NewsUSA) - The anti-inflammatory medication dupilumab, marketed as Dupixent, is the subject of a lawsuit alleging a link between the use of the medication and the development of a type of skin cancer known as cutaneous T-cell lymphoma (CTCL).

Dupixent is prescribed for several medical conditions including asthma and eczema. CTCL is a type of skin cancer that develops in white blood cells, which help the body fight infection.

Early signs and symptoms of CTCL include red, scaly patches, rashes, lumps and bumps, discoloration, thickened skin, swollen lymph nodes, hair loss, itching, fever and chills, unexplained weight loss, pain or tenderness, and night sweats. As CTCL progresses, the visual changes can affect up to 80% of the skin’s surface. Ultimately, the disease can spread to internal organs, including the spleen and liver.

Dupixent manufacturers Regeneron Pharmaceuticals and Sanofi Genzyme failed to adequately warn of the risks in taking the drug, according to Ellen Relkin, partner in the law firm of Weitz & Luxenberg and practice group chair of the firm’s Drug and Medical Device Litigation team. The law firm of Weitz & Luxenberg is taking legal cases for patients who have and used an anti-inflammatory medication and have been diagnosed with skin cancer.

“Cutaneous T-cell lymphoma is a very rare type of skin cancer. This makes it all the more critical for the manufacturer to warn patients about the danger,” states Relkin.

A study in the Journal of the American Academy of Dermatology reported an increased risk of CTCL was found in a cohort of atopic dermatitis patients who used dupilumab. “The increased risk persisted after exclusion of prior disease-modifying antirheumatic drug use. Risk was not increased for other cutaneous or lymphoid malignancies,” the researchers wrote.

“Doctors and patients alike need to be sufficiently warned, and patients who take Dupixent, and their doctors, need to keep a careful eye out for any disturbing changes to their skin,” says Ms. Relkin.  

“Those who took Dupixent and are suffering deserve compensation. And we are going to help you get it,” she insists.

Weitz & Luxenberg is encouraging anyone diagnosed with CTCL who used Dupixent to contact the firm for information about legal options and a free initial consultation. Call (917) LAWYERS or visit https://www.weitzlux.com/firm-news/dupixent-skin-cancer-lawsuit-ctcl/.

 

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.